Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA

Executive Summary

Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.


Related Content

Industry Groups Seek More Options In Responding To DSCSA Verification Requests
Pharmaceutical Manufacturers Testing Use of Verification Router Services To Process Saleable Returns Under DSCSA
Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline
Some Double Bar-Coding Required After November DSCSA Deadline, US FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts